B cell activating factor is elevated in acute idiopathic thrombotic thrombocytopenic purpura

British Journal of Haematology

Volumn 155, Issue 5, 2011, Pages 620-622

  Thomas, Mari R ^a   Machin, Samuel J ^a   Mackie, Ian ^a   Scully, Marie A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; B cell activating factor; ELISA; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; AGED; B CELL ACTIVATING FACTOR BLOOD LEVEL; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LETTER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RELAPSE;

ADOLESCENT; ADULT; AGED; ANIMALS; B-CELL ACTIVATING FACTOR; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; YOUNG ADULT;

EID: 81155134914     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08730.x     Document Type: Letter

References (10)

1. Cambridge, G., Isenberg, D., Edwards, J., Leandro, M., Migone, T.-S., Teodorescu, M. & Stohl, W. (2008) B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Annals of the Rheumatic Diseases, 67, 1011-1016.
2. Davidson, A. (2010) Targeting BAFF in autoimmunity. Current Opinion in Immunology, 22, 732-739.
3. Emmerich, F., Bal, G., Barakat, A., Milz, J., Mühle, C., Martinez-Gamboa, L., Dörber, T. & Salama, A. (2006) High levels of serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. British Journal of Haematology, 136, 309-314.
4. Mackay, F. & Schneider, P. (2009) Cracking the BAFF code. Nature Reviews Immunology, 9, 491-502.
5. Mackay, F., Woodcock, S.A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tscopp, J. & Browning, J.L. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. Journal of Experimental Medicine, 190, 1697-1710.
6. Miller, R.F., Scully, M., Cohen, H., Roedling, S., Starke, R., Edwards, S.G. & Machin, S.J. (2005) Thrombotic thrombocytopenic purpura in HIV-infected patients. International Journal of STD & AIDS, 16, 538-542.
7. Scully, M., Brown, J., Patel, R., McDonald, V., Brown, C.J. & Machin, S. (2009) Human leukocyte antigen association in idiopathic thrombocytopenic purpura: evidence for an immunogenetic link. Journal of Thrombosis and Haemostasis, 8, 257-262.
8. Shariatmader, S., Nassiri, M. & Vincek, V. (2005) Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura. American Journal of Hematology, 79, 83-88.
9. Zhu, X.J., Shi, Y., Peng, J., Guo, C.S., San, N.N., Qin, P., Ji, X.B. & Hou, M. (2009a) The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood, 114, 5362-5367.
10. Zhu, X.J., Shi, Y., Sun, J.Z., Shan, N.N., Peng, J., Guo, C.S., Qin, P. & Hou, M. (2009b) High dose dexamathasone inhibits BAFF expression in patients with immune thrombocytopenia. Journal of Clinical Immunology, 29, 603-610.